Article: Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus on Leukemias and Lymphomas.

Article: Research and Markets: Triple Analysis: Decoding Big ...
Business Wire;  February 15, 2008 ;     700+ words ... ... Analysis: Decoding Big Pharma's R& ... in Oncology and Special Focus on Leukemias and ... interested to grasp big pharma's R& ... indications - Special focus on Angiogenesis ... between the five big pharma includes more ...

Article: Gain Insight into Decoding Big Pharma's R&D ...
Business Wire;  September 24, 2007 ;     700+ words ... ... decodes' these five big pharma R&D efforts into ... decisions. Decoding Big Pharma's R&D Strategy ... supportive care indications * Special focus on Angiogenesis-, Antibody ... landscape between the five big pharma includes more than 200 ...

Article: Financial and Strategic Analysis of the Sales Outlook for ...
Business Wire;  February 12, 2007 ;     700+ words ... ... Strategic Analysis of the Sales Outlook for Big Pharma, Mid Pharma, Japan Pharma and Biotech ... Analysis of the Sales Outlook to 2011 for Big Pharma, Mid Pharma, Japan Pharma and Biotech ... Highlights Faced with failing growth, Big Pharma is expected to pursue strategic options ...

Article: Key Challenges and Issues Facing the Pharmaceutical Company ...
Business Wire;  January 20, 2008 ;     700+ words ... ... Strategic Analysis of the Sales Outlook for Big Pharma, Mid Pharma, Japan Pharma and Biotech ... of-the-Sales-Outlook-for-Big- Pharma-Mid-Pharma-Japan-Pharma-and ... Analysis of the Sales Outlook to 2012 for Big Pharma, Mid Pharma, Japan Pharma and Biotech ...

Article: A Comprehensive Big Pharma M&A Analysis to 2012 - ...
M2 Presswire;  October 13, 2008 ;     700+ words ... ... Research and Markets: A Comprehensive Big Pharma M&A Analysis to 2012 - Surveying ... researchandmarkets.com/research/fa352c/big_pharma_ma_ana) has announced the addition of the "Big Pharma M&A Analysis to 2012 - Surveying ...

Article: A Comprehensive Big Pharma M&A Analysis to 2012 - ...
Business Wire;  October 13, 2008 ;     700+ words ... ... researchandmarkets.com/research/ed3063/big_pharma_ma_ana) has announced the addition of the "Big Pharma M&A Analysis to 2012 - Surveying ... to fall below their historic levels, Big Pharma must act to bolster its performance out ...

Article: BIO-EUROPE 2007 AS BIG PHARMA MODEL FALTERS, ...
BIOWORLD Today;  November 13, 2007 ;     700+ words ... ... BIO-Europe 2007. "What is it about big pharma that allows the strong to become weak ... produced no vehement rebuttals even from big pharma representatives at Monday's panel on ... have a high innovation environment at a big pharma," he said. "It's hard for me to ...